Foreign investors are stepping up acquisitions of Japanese drug makers. Under the Foreign Exchange and Foreign Trade Act (FEFTA), such…
BUSINESS
Takeda Gets US Clearance for Hutchmed’s Colorectal Cancer Drug
Takeda Pharmaceutical said on November 8 that the US FDA has given the green light to fruquintinib, a tyrosine kinase inhibitor licensed from Chinese biopharma Hutchmed, for the treatment of certain patients with previously treated metastatic colorectal cancer (CRC). The…
To read the full story
Related Article
- Takeda Scores EU Approval for Colorectal Cancer Med Fruzaqla
June 25, 2024
- Takeda Seeks Japan Nod for Hutchmed’s Colorectal Cancer Drug
October 2, 2023
- Hutchmed’s Colorectal Cancer Med Accepted for European Review: Takeda
June 19, 2023
- Hutchmed’s Colorectal Cancer Med Gets FDA’s Priority Review: Takeda
May 29, 2023
- Hutchmed’s Colorectal Cancer Med Logs Positive Data in Japanese Cohort: Takeda
March 24, 2023
- Takeda Gets Rights to Hutchmed’s Colorectal Cancer Med Outside China
January 25, 2023
BUSINESS
- Kisunla Uptake “as Expected” One Year after Approval, Says Lilly Japan Exec
September 19, 2025
- SanBio Eyes Akuugo Label Expansion Talks with PMDA in FY2026
September 19, 2025
- Deciphera’s Romvimza Scores EU Nod as First TGCT Therapy
September 19, 2025
- Lilly Japan Adds Tablet Formulation for Retevmo
September 19, 2025
- Nihon Chouzai Tender Offer Completed, Set to Delist under Advantage Partners
September 18, 2025
MSD’s new pulmonary arterial hypertension (PAH) therapy Airwin (sotatercept) hit the Japanese market in mid-August. It’s the kind of launch…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…